Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ChAdOx2 RabG in healthy adults
NCT04162600Phase 1Terminated
- Sponsor
- University of Oxford
- Start
- Jan 2020
- Primary completion
- Jul 2024
- Countries
- 1
01
Overview
Phase 1, open-label trial of ChAdOx2 RabG in rabies, sponsored by University of Oxford. Primary endpoint: Solicited Adverse Events at 7 days. Started Jan 2020; status: terminated.
02
Drugs
ChAdOx2 RabG
03
Conditions
rabies
Beyond the preview
Go deeper on NCT04162600.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04162600.